» Articles » PMID: 31855835

Hydrophobically Modified Let-7b MiRNA Enhances Biodistribution to NSCLC and Downregulates HMGA2 In Vivo

Overview
Publisher Cell Press
Date 2019 Dec 20
PMID 31855835
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) have increasingly been shown to be involved in human cancer, and interest has grown about the potential use of miRNAs for cancer therapy. miRNA levels are known to be altered in cancer cells, including in non-small cell lung cancer (NSCLC), a subtype of lung cancer that is the most prevalent form of cancer worldwide and that lacks effective therapies. The let-7 miRNA is involved in the regulation of oncogene expression in cells and directly represses cancer growth in the lung. let-7 is therefore a potential molecular target for tumor therapy. However, applications of RNA interference for cancer research have been limited by a lack of simple and efficient methods to deliver oligonucleotides (ONs) to cancer cells. In this study, we have used in vitro and in vivo approaches to show that HCC827 cells internalize hydrophobically modified let-7b miRNAs (hmiRNAs) added directly to the culture medium without the need for lipid formulation. We identified functional let-7b hmiRNAs targeting the HMGA2 mRNA, one of the let-7 target genes upregulated in NSCLC, and show that direct uptake in HCC827 cells induced potent and specific gene silencing in vitro and in vivo. Thus, hmiRNAs constitute a novel class of ONs that enable functional studies of genes involved in cancer biology and are potentially therapeutic molecules.

Citing Articles

Frameworks for transformational breakthroughs in RNA-based medicines.

Androsavich J Nat Rev Drug Discov. 2024; 23(6):421-444.

PMID: 38740953 DOI: 10.1038/s41573-024-00943-2.


Applications of Exosomal miRNAs from Mesenchymal Stem Cells as Skin Boosters.

Zheng J, Yang B, Liu S, Xu Z, Ding Z, Mo M Biomolecules. 2024; 14(4).

PMID: 38672475 PMC: 11048182. DOI: 10.3390/biom14040459.


The RAS oncogene in brain tumors and the involvement of let-7 microRNA.

Messina S Mol Biol Rep. 2024; 51(1):531.

PMID: 38637419 PMC: 11026240. DOI: 10.1007/s11033-024-09439-z.


Exploring the Impact of Exosomal Cargos on Osteosarcoma Progression: Insights into Therapeutic Potential.

Chen C, Benavente C Int J Mol Sci. 2024; 25(1).

PMID: 38203737 PMC: 10779183. DOI: 10.3390/ijms25010568.


miRNA-Based Technologies in Cancer Therapy.

Pagoni M, Cava C, Sideris D, Avgeris M, Zoumpourlis V, Michalopoulos I J Pers Med. 2023; 13(11).

PMID: 38003902 PMC: 10672431. DOI: 10.3390/jpm13111586.


References
1.
Kortylewski M, Nechaev S . How to train your dragon: targeted delivery of microRNA to cancer cells in vivo. Mol Ther. 2014; 22(6):1070-1071. PMC: 4048907. DOI: 10.1038/mt.2014.73. View

2.
. Retraction: HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature. 2015; 523(7560):370. PMC: 4527149. DOI: 10.1038/nature14551. View

3.
McDermott A, Heneghan H, Miller N, Kerin M . The therapeutic potential of microRNAs: disease modulators and drug targets. Pharm Res. 2011; 28(12):3016-29. DOI: 10.1007/s11095-011-0550-2. View

4.
Deleavey G, Damha M . Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol. 2012; 19(8):937-54. DOI: 10.1016/j.chembiol.2012.07.011. View

5.
Shmushkovich T, Monopoli K, Homsy D, Leyfer D, Betancur-Boissel M, Khvorova A . Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs. Nucleic Acids Res. 2018; 46(20):10905-10916. PMC: 6237813. DOI: 10.1093/nar/gky745. View